Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.

CONCLUSION: We developed a clinically relevant signature for patients with chemoresistant TNBC. For these women, new therapeutic strategies like targeting AR activation or cancer stem cells may need to be developed. Clin Cancer Res; 19(10); 2723-33. ©2013 AACR. PMID: 23549873 [PubMed - in process]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research